27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Goldman Sachs is downgrading Spark Therapeutics Inc (NASDAQ:ONCE) after the pharma startup presented disappointing data on its hemophilia A gene therapy at the annual meeting of the American Society of Hematology on Monday.
The Analyst
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Goldman Sachs' Salveen Richter downgraded Spark Therapeutics from Buy to Neutral and lowered the price target to $58 from $106.
The Thesis
Sparks remains a leading gene therapy company, but it has limited value-driving catalysts in 2018, Richter said. (See Richter's track record here.)
Goldman is projecting U.S. approval for Luxturna approval by Jan. 12, with a decent likelihood of a successful launch. There are also some preclinical assets that could enter clinic, like a liver disease-focused asset in-licensed from Genethon and drugs for Batten disease, Huntington's disease and the opthalmological disease Leber hereditary optic neuropathy, Richter said.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
The price target of Spark Therapeutics was calculated by averaging the sum-of-parts valuation of $70 and the discounted cash flow valuation of $45, Richter said. Goldman projects the takeover probability for Spark at zero to 15 percent.
The Price Action
Spark's stock dropped around 35 percent Monday after the company presented weak hemophilia A gene therapy data. The stock was trading 1.68 percent lower at $45.14 at the time of publication.
Related Links:
11 Biotech Stocks Moving From ASH 2017
Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.